Feedback received was strongly positive about the event:
Amphetamine Type Stimulants (ATS), such as amphetamine, methamphetamine, MDMA, and some Novel Psychoactive Substances (NPS), are commonly used drugs in Europe.The presentations in this session draw on the findings from the ongoing multinational ERANID/Department of Health ‘ATTUNE’ project and N8 Policing Partnership-funded NPS work to explore different ATS use careers, with a particular focus on North East England.
Professor Eileen Kaner
Mr Chris Strachan
Animal research suggests that exercise reduces consumption of various substances when addicted and identifies a number of possible mechanisms through neurobiological processes. The last 10-15 years has seen exponential growth in human research, from laboratory studies on effects of PA on cravings, functional brain responses, and attentional bias to relevant cues, through to large trials with various populations and outcomes. Much of the research to date has focused on nicotine addiction, but there is a rapidly growing interest in interventions to support other addictions.
Professor Adrian H Taylor
Miss Sophie Betka
For the launch of its latest edition, Professor Sir John Strang will introduce the influential and highly-regarded Drug Policy & the Public Good, followed by more detailed contributions by some of its co-authors:
Professor Ingeborg Rossow
Professor Keith Humphreys
Professor David Foxcroft
Concern about health inequalities among people at the end of their lives has been the subject of increased policy attention. Current UK policy emphasises the importance of equality of care but little is known about whether this extends to people with problematic substance use who are often marginalised in health care provision. As the population ages and a growing number of older people present to health services with substance-related health problems, the issue of end of life care is called into focus. It raises questions about whether current services meet the needs of this population and whether resources are equally accessible to them.
Professor Sarah Galvani
The psychedelic group of compounds are undergoing a renaissance in the treatment of psychiatric and addictive disorders. This session provides an update on the underlying science and the latest research for psychedelic-assisted therapies as novel addiction treatments.
Dr Suzi Gage
Dr Albert Garcia-Romeu